NCT01457495已完成2 期
Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 312
- 主要终点
- Number of subjects with antibody titers equal to or greater than cut-off value.
研究概览
简要总结
This study will assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared to the separate administration of DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines administered at 3 and 5 months of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 12 Weeks 至 16 Weeks（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or female between 12 and 16 weeks of age at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the parents or guardians of the subject after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.
排除标准
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
- •Administration of chronic immunosuppressants or immune-modifying drugs during the study period.
- •Administration of a vaccine not foreseen by the study protocol during the period starting from one month before each dose and ending one month after each dose.
- •Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib diseases.
- •History of/or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- •History of allergic disease or reaction likely to be exacerbated by any component of the vaccine, including allergic reactions to neomycin and polymyxin B.
- •Major congenital defects or serious chronic illness.
- •Progressive neurological disorders.
- •Administration of immunoglobulins and/or any blood products since birth and during the study period.
- •Acute febrile illness at the time of planned vaccination.
结局指标
主要结局
Number of subjects with antibody titers equal to or greater than cut-off value.
时间窗: One month after the 2nd dose of the primary vaccination course (month 3)
次要结局
- Immunogenicity with respect to components of the study vaccines in terms of antibody titers(One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9))
- Occurrence of unsolicited symptoms(Within 30 days after each vaccination, and overall)
- Occurrence of solicited local symptoms(Within 4 days after each vaccination and overall)
- Immunogenicity with respect to components of the study vaccines in terms of number of seropositive subjects(One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9))
- Immunogenicity with respect to components of the study vaccines in terms of number of subjects with a vaccine response(One month after the 3rd dose of the primary vaccination course (Month 9))
- Occurrence of solicited general symptoms(Within 4 days after each vaccination and overall)
- Occurrence of serious AEs(Throughout the entire study (approximately 9 months per subject) up to and including 30 days post-vaccination)
研究者
相似试验
已完成
3 期
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyHaemophilus Influenzae Type b (Hib)PoliomyelitisHepatitis BTetanusDiphtheriaPertussisNCT01457508GlaxoSmithKline440
已完成
3 期
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineAcellular PertussisHaemophilus Influenzae Type bPoliomyelitisHepatitis BTetanusDiphtheriaNCT01457560GlaxoSmithKline80
已完成
3 期
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®Acellular PertussisDiphtheriaTetanusNCT01277705GlaxoSmithKline806
已完成
3 期
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenInfluenzaNCT01196988GlaxoSmithKline3,027
已完成
3 期
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female SubjectsInfections, PapillomavirusNCT00996125GlaxoSmithKline750